Point72 Asset Management
INMB icon

Point72 Asset Management’s INmune Bio INMB Stock Holding History

Point72 Asset Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27K Buy
+16,577
New +$22.9K ﹤0.01% 3854
2020
Q4 		– Sell
-100,000
Closed -$1.03M – 1016
2020
Q3 		$1.03M Buy
+100,000
New +$1.02M 0.01% 775

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Point72 Asset Management's INMB Position: Q2 2026 in Review

Point72 Asset Management opened a new position in INmune Bio (INMB) in Q2 2026: 16,577 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #3854 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in INMB as recently as Q3 2020.

Point72 Asset Management first reported a position in INMB in Q3 2020 and has held it in 2 quarters since. The position peaked at $1.03M in Q3 2020. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Point72 Asset Management held 16,577 shares of INmune Bio worth $27K as of Q2 2026.
  • INmune Bio was a new Point72 Asset Management position in Q2 2026.
  • INmune Bio made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3854 holding.
  • Point72 Asset Management first reported a position in INmune Bio in Q3 2020 and has held it in 2 quarters since.
  • Point72 Asset Management's INmune Bio position peaked at $1.03M in Q3 2020.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.